secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0000784199-21-000183
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CryoLife sells PerClot to Baxter for up to $60.8M; Q2 revenue up 42% to $76.1M
------------------------------------------------------------------------------

- Total consideration up to $60.8M: $25M at closing ($19M to CryoLife), $25M upon FDA PMA approval, $10M sales milestones.
- CryoLife retains FDA costs through Dec 31, 2022; Baxter may assume after Jan 1, 2023.
- Q2 2021 revenue $76.1M, up 42% GAAP vs Q2 2020 $53.8M; net loss ($2.2M) ($0.06/shr); non-GAAP net income $4.8M ($0.12/shr).
- FY2021 revenue guidance $296-300M; Q3 2021 expected $71-73M, with PerClot minimal in H2 due to sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419921000183/0000784199-21-000183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419921000183/cry-20210729x8k.htm
  HTML page:      https://secwatch.observer/filing/0000784199-21-000183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer